Jeffrey W. Albers sold $2.4M of Spyre Therapeutics (SYRE)

Executed Aug 7, disclosed Aug 11, 3 days later.

Value, as filed

$2.4M

23,000 sh across 3 lots

Executed

Aug 7

the trade date, as filed

Disclosed

Aug 11

3 days after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

–

purchases only

Returns are measured on stock purchases only.

The filer

JA Jeffrey W. Albers Director profile →

Jeffrey W. Albers (Director) filed 3 Form 4 reports in the trailing twelve months (0 purchases, 3 sales), most often in BPMC. The largest single filing was $2.4M of SYRE (23,000 sh across 3 lots, as filed), executed Aug 7.

The name

SYRE

Spyre Therapeutics, Inc. SYRE · Healthcare · 29 filings in 24 months ticker →

Healthcare · Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→

Other filings by Jeffrey W. Albers in SYRE

SYRESALE Spyre Therapeutics, Inc. $246K
6,700 sh × $36.76
Exec Nov 6 2024
Filed Nov 8 2024 · 5:30 PM ET